Edition:
India

Vermillion Inc (VRML.OQ)

VRML.OQ on NASDAQ Stock Exchange Capital Market

1.74USD
10:49pm IST
Change (% chg)

$0.10 (+6.10%)
Prev Close
$1.64
Open
$1.65
Day's High
$1.75
Day's Low
$1.62
Volume
5,024
Avg. Vol
12,932
52-wk High
$2.85
52-wk Low
$0.91

Summary

Name Age Since Current Position

James LaFrance

58 2015 Chairman of the Board

Valerie Palmieri

53 2015 President, Chief Executive Officer

Fred Ferrara

49 2016 Chief Operating Officer

Donald Munroe

58 2013 Senior Vice President - Business Development, Chief Scientific Officer

Eric Schoen

46 2013 Chief Accounting Officer, Vice President - Finance

James Burns

69 2013 Independent Director

Veronica Jordan

64 2014 Independent Director

David Schreiber

55 2014 Independent Director

Carl Severinghaus

63 2010 Independent Director

Eric Varma

33 2013 Independent Director

Ron Both

IR Contact Officer

Biographies

Name Description

James LaFrance

Mr. James T. LaFrance is the Chairman of the Board of Company., since January 1, 2015. He is no longer President, Chief Executive Officer of the Company. Mr. LaFrance was elected to the Board in December 2013 and has served as Chairman of the Board since December 2013. Mr. LaFrance has almost 30 years of diagnostic industry experience. Most recently, Mr. LaFrance was head of digital pathology and acting Chief Executive Officer of Omnyx, LLC for GE Healthcare, a medical technology provider. Prior to that, he held a series of commercial, strategic marketing and business development leadership roles at Ventana Medical Systems, Inc. (now Roche Tissue Diagnostics), a provider of tissue-based diagnostic solutions, including general manager of their North American and International commercial organizations. Prior to Ventana, Mr. LaFrance served in leadership roles in strategic marketing and business development at Bayer Diagnostics. He was a member of the board at Mitomics, Inc. from 2010 to 2011. He earned a Bachelor of Arts degree in Economics from the University of Connecticut and an MBA from the University of Notre Dame.

Valerie Palmieri

Ms. Valerie Barber Palmieri is the President, Chief Executive Officer of Vermillion, Inc., since January 1, 2015. She is no longer Chief Operating Officer of Vermillion, Inc., effective October 23, 2014. Ms. Palmieri was President, Founder and Managing Member of MOMENTUM Consulting, L.L.C. (“MOMENTUM”) beginning in April 2009. MOMENTUM is a consulting firm focused on esoteric diagnostic services, including clinical, anatomic and molecular pathology. In 2012, Ms. Palmieri founded LifeCycle Laboratories, LLC, a provider of diagnostic tests for fertility/infertility management, and she served as its Chief Executive Officer from July 2012 to January 2014. From April 2010 to July 2011, Ms. Palmieri served as President of the U.S. division of DiagnoCure Inc., a provider of diagnostic tests for the detection and management of cancer. From 2003 to 2009, Ms. Palmieri served as National Vice President of Anatomic Pathology Operations with Laboratory Corporation of America, a company that commercializes new diagnostic technologies.

Fred Ferrara

Mr. Fred Ferrara serve as Chief Operating Officer of the Company. Mr. Ferrara has served as the Company’s Chief Information Officer since April 2015. Prior to joining the Company, Mr. Ferrara spent 24 years designing industry-specific systems in information technology, including application and database development, with the previous 17 years solely dedicated to diagnostics companies. He served in numerous leadership roles in information technology and operations, and he served in senior leadership capacities for diagnostic service organizations such as Laboratory Corporation of America and DIANON Systems. In August 2014, Mr. Ferrara founded Key Mobile Systems, working as an independent information systems consultant in the healthcare and mobile application markets. From August 2006 to August 2014, Mr. Ferrara served as Chief Information Officer and Senior Vice President of Aurora Diagnostics, LLC, an anatomic pathology services company.

Donald Munroe

Dr. Donald G. Munroe, Ph.D., is the Senior Vice President , Business Development, Chief Scientific Officer of Vermillion, Inc. Dr. Munroe has extensive experience in the diagnostic industry, and has been a key member of upper management in a number of prominent diagnostic and life science companies. He served as Vice President, Immunoassay Research and Development from 2009 to 2011 at Beckman Coulter, a preeminent manufacturer of automated diagnostic tests and biomedical instruments. In this role, Dr. Munroe was responsible for launching key Immunoassay menu additions and re-standardizing existing assays. He also initiated manufacturing science investigations and product improvement projects. Previously, Dr. Munroe worked at Invitrogen Corporation in several roles including Vice President, Research and Development (Transplant Diagnostics) from 2006 to 2008, Vice President, Global Program and Portfolio Management (Corporate) from 2004 to 2005, and Director, Research and Development (GIBCO™) from 2002 to 2003. Dr. Munroe was Director of Technology Commercialization with Corning (Microarray Technologies) from 2000 to 2002, and has 10 years of pharmaceutical discovery research experience at R.W. Johnson Pharmaceutical Research Institute (1990 to 1995) and Allelix Biopharmaceuticals (1996 to 2000). Dr. Munroe received his Bachelor of Science in Biology from the University of Guelph, Master of Science in Medical Sciences at McMaster University and Ph.D. in Medical Biophysics at University of Toronto. Dr. Munroe has served as a member of the Scientific Advisory Board of Minneapolis Community & Technical College and is an associate member of the Society of Gynecologic Oncology, and a member of the American Association for Clinical Chemistry and the American Association for the Advancement of Science. Dr. Munroe is an inventor in seven granted U.S. patents, and has authored peer-reviewed publications on the molecular basis of cancer, gastrointestinal disorders, inflammation, OVA1 clinical validation and other topics.

Eric Schoen

Mr. Eric J. Schoen is the Chief Accounting Officer, Vice President - Finance of Vermillion, Inc. He was named Vice President, Finance on May 28, 2013 and has been our Chief Accounting Officer since October 2011. Prior to joining the Company, Mr. Schoen served as Revenue Controller for Borland Software, a publicly traded software development company, from 2007 to 2010. From 2000 to 2007, he served in Corporate Controller and Director of Finance roles for Trilogy Enterprises, Momentum Software and Alticast, Inc. Mr. Schoen also spent nine years with PricewaterhouseCoopers, most recently as a Manager in the audit and assurance, transaction services and global capital markets practices. Mr. Schoen received his Bachelor of Science in Finance from Santa Clara University.

James Burns

Mr. James S. Burns is the Independent Director of Vermillion Inc. He is a member of our Audit Committee. Mr. Burns is currently Chief Executive Officer and director of AssureRx, Health, Inc., a personalized medicine company which specializes in pharmacogenetics for neuropsychiatric disorders. Prior to joining AssureRx, Health, Inc., Mr. Burns was the President and Chief Executive Officer of EntreMed, Inc. from June 2004 to December 2008, and a director from September 2004 to December 2008. Mr. Burns was a co-founder and, from 2001 to 2003, served as President and as Executive Vice President of MedPointe, Inc., a specialty pharmaceutical company that develops, markets and sells branded prescription pharmaceuticals. From 2000 to 2001, Mr. Burns served as a founder and Managing Director of MedPointe Capital Partners, a private equity firm that led a leveraged buyout to form MedPointe Pharmaceuticals. Previously, Mr. Burns was a founder, Chairman, President and Chief Executive Officer of Osiris Therapeutics, Inc., a biotech company developing therapeutic stem cell products for the regeneration of damaged or diseased tissue. Mr. Burns has also been Vice Chairman of HealthCare Investment Corporation and a founding General Partner of Healthcare Ventures L.P., a venture capital partnership specializing in forming companies building around new pharmaceutical and biotechnology products; Group President at Becton Dickinson and Company, a multidivisional biomedical products company; and Vice President and Partner at Booz & Company, Inc., a multinational consulting firm. Mr. Burns is a director of Symmetry Medical Inc. (NYSE: SMA), a supplier of products and services to orthopedic and other medical device companies. Mr. Burns received his B.S. and M.S. in Biological Sciences from the University of Illinois, and M.B.A. from DePaul University. He has also earned a Board Leadership Fellow certification from the National Association of Corporate Directors.

Veronica Jordan

Dr. Veronica G. H. Jordan, Ph.D., is the Independent Director of the Company. She is an accomplished entrepreneur and international business leader. As an advisor to life science and healthcare firms, she brings to Vermillion significant experience in all aspects of the business cycle from raising capital, integrating acquisitions and negotiating licensing and partnership arrangements to business development and sales and marketing. From 2001-2006, she was President/CEO and a director of Medelle Corporation, a private, venture capital funded medical device company in women's health. Prior to that she served for fourteen years in various executive positions at PAREXEL International. Earlier, she held business and international leadership roles at Biogen Idec and managed an R&D department for Baxter International. Dr. Jordan currently serves on the board of Albany Molecular Research Inc. a global contract drug discovery, development, and manufacturing company. She also serves on the Boards of a number of not-for-profit organizations working to advance various healthcare initiatives. Dr. Jordan received her Bachelor of Arts in Biochemistry from Cambridge University and her Ph.D. in Biochemistry/Cell Biology from Oxford University. She is a member of the National Association of Corporate Directors, Board Leaders, Corporate Directors Group, Women's Corporate Directors, and Women Business Leaders in US Healthcare Industry.

David Schreiber

Mr. David R. Schreiber is the Independent Director of Company. David Schreiber has more than 30 years of corporate and consulting experience in the healthcare industry, particularly in the area of corporate finance, operations, and mergers and acquisitions. Since 2004, he has provided consulting services on a wide variety of healthcare projects including Welsh Carson Anderson & Stowe's 2014 sale of Solstas Lab Partners to Quest Diagnostics and the 2007 sale of Ameripath/Specialty Laboratories to Quest. In addition, he currently supports M&A due diligence research in the lab industry for Warburg Pincus. His corporate experience includes serving as Senior Vice President & Chief Financial Officer of publicly traded DIANON Systems from 1996 until its successful sale to LabCorp in 2003. He has also served in key management roles at Corning Clinical Laboratories and Unilab Corporation. He currently serves on the board of directors of Response Genetics, Inc. and has served on the boards of Nanogen, Inc., DIANON Systems and Specialty Laboratories, Inc., where he served as interim CEO/CFO to oversee its turnaround and subsequent sale. Mr. Schreiber received his Bachelor of Science in Finance and his Masters In Business Administration from Northern Illinois University.

Carl Severinghaus

Mr. Carl Severinghaus is the Independent Director of Vermillion Inc. Since January 1,2011. In addition, he is a member of our Audit Committee and also our Nominating and Governance Committee. Since January 1, 2011, Mr. Severinghaus is Vice President, Head Global Sales OEM Components of the Tecan Group, a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. Previously from 2009 until 2011 he was President of Tecan Americas, responsible for Sales and Commercial Operations for the Americas Region, including US, Canada, Central and South America. From 2007 until 2009, he lived in Zurich and was Senior Vice President for International Sales at Tecan, responsible for Worldwide Sales and Operations. From 1999 to 2007, Mr. Severinghaus was President and General Manager of Tecan US. Prior to becoming President and General Manager at Tecan, he was Vice President of Sales from 1991 to 1998. Before he joined Tecan he was National Sales Manager for American Monitor Corporation. Mr. Severinghaus received his Bachelor of Fine Arts Degree from Drake University in 1974. Mr. Severinghaus is or has been a member of the Analytical & Life Science System Association, Society for Laboratory Automation and Screening (SLAS) and also the American Association of Clinical Chemistry (AACC).

Eric Varma

Dr. Eric K. Varma, M.D., is the Independent Director of Vermillion, Inc., effective September 12, 2013. Dr. Varma is currently a partner at Oracle Investment Management, Inc., which is a fundamental research-driven investment management company that is exclusively focused on the global health care and bioscience industries. Prior to joining Oracle Investment Management in 2009, he worked at Leerink Swann, a healthcare investment bank, the Boston Consulting Group, and the Food and Drug Administration. Dr. Varma received his B.A. from the University of California Berkeley, M.D. from the Albert Einstein College of Medicine, and M.B.A. from the MIT Sloan School of Management.

Ron Both

Basic Compensation